Evidence map›Paper›PMID 28061753›Full record

ArticleBMC infectious diseases2017

Treatment efficacy of azithromycin 1 g single dose versus doxycycline 100 mg twice daily for 7 days for the treatment of rectal chlamydia among men who have sex with men - a double-blind randomised controlled trial protocol.

Andrew Lau, Fabian Kong, Christopher K Fairley, Basil Donovan, Marcus Chen, Catriona Bradshaw, Mark Boyd, Janaki Amin, Peter Timms, Sepehr Tabrizi and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 18 citations in OpenAlex.

  1. Doxycycline Versus Azithromycin for the Treatment of Rectal Chlamydia in Men Who Have Sex With Men: A Randomized Controlled Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Trial
  2. Article
  3. Microorganisms · 2019
    Review
  4. Observational
  5. Outcomes of Resistance-guided Sequential Treatment of Mycoplasma genitalium Infections: A Prospective Evaluation.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

Andrew LauCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Carlton, 3053, VIC, Australia.ORCID 0000-0002-5240-8468
Fabian KongCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Carlton, 3053, VIC, Australia.
Christopher K FairleyMelbourne Sexual Health Centre, Alfred Health, 580 Swanston St, Carlton, 3053, VIC, Australia.
Basil DonovanThe Kirby Institute, UNSW Australia, Kensington, 2052, NSW, Australia.
Marcus ChenMelbourne Sexual Health Centre, Alfred Health, 580 Swanston St, Carlton, 3053, VIC, Australia.
Catriona BradshawCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Carlton, 3053, VIC, Australia.
Mark BoydThe Kirby Institute, UNSW Australia, Kensington, 2052, NSW, Australia.
Janaki AminThe Kirby Institute, UNSW Australia, Kensington, 2052, NSW, Australia.
Peter TimmsUniversity of the Sunshine Coast, 90 Sippy Downs Drive, Sippy Downs, 4556, QLD, Australia.
Sepehr TabriziDivision of Laboratory Services, Department of Microbiology, University of Melbourne, Carlton, 3053, VIC, Australia.
David G ReganThe Kirby Institute, UNSW Australia, Kensington, 2052, NSW, Australia.
David A LewisWestern Sydney Sexual Health Centre, 162 Marsden St, Parramatta, 2150, NSW, Australia.
Anna McNultySydney Sexual Health Centre, Level 3 Nightingale Wing, Sydney Hospital, Macquarie St, Sydney, 2000, NSW, Australia.
Jane S HockingCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Carlton, 3053, VIC, Australia. j.hocking@unimelb.edu.au.
The University of Melbourne · AUAustralian Wool Innovation (Australia) · AUMelbourne Sexual Health Centre · AUSydney Hospital · AUSydney Sexual Health Centre · AUUniversity of the Sunshine Coast · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRectal infection with Chlamydia trachomatis is one of the most common bacterial sexually transmissible infections among men who have sex with men (MSM) with diagnosis rates continuing to rise. Current treatment guidelines recommend either azithromycin 1 g single dose or doxycycline 100 mg twice daily for 7 days. However, there are increasing concerns about treatment failure with azithromycin. We are conducting the first randomised controlled trial (RCT) to compare treatment efficacy of azithromycin versus doxycycline for the treatment of rectal chlamydia in MSM. METHODS/

designThe Rectal Treatment Study will recruit 700 MSM attending Australian sexual health clinics for the treatment of rectal chlamydia. Participants will be asked to provide rectal swabs and will be randomised to either azithromycin 1 g single dose or doxycycline 100 mg twice daily for 7 days. Participants will be asked to complete questionnaires about adverse drug reactions, sexual behaviour and drug adherence via short message service and online survey. The primary outcome is the treatment efficacy as determined by a negative chlamydia nucleic acid amplification test at 4 weeks post treatment. Secondary outcomes will utilise whole genome sequencing and mRNA assay to differentiate between treatment failure, reinfection or false positive results. DISCUSSION: Rectal chlamydia is an increasing public health concern as use of pre-exposure prophylaxis against HIV becomes commonplace. Optimal, evidence-based treatment is critical to halting ongoing transmission. This study will provide the first RCT evidence comparing azithromycin and doxycycline for the treatment of rectal chlamydia. The results of this trial will establish which treatment is more efficacious and inform international management guidelines.

trial registrationAustralian New Zealand Clinical Trials Registry ACTRN12614001125617.

Indexed as

AdultAnti-Bacterial AgentsAustraliaAzithromycinChlamydia InfectionsChlamydia trachomatisClinical ProtocolsDouble-Blind MethodDoxycyclineDrug Administration ScheduleHomosexuality, MaleHumansMaleNucleic Acid Amplification TechniquesRandomized Controlled Trials as TopicRectal DiseasesAnti-Bacterial AgentsAzithromycinDoxycyclineazithromycinChlamydiadoxycyclineMSMrectaltreatment

Identifiers

PMID28061753
PMCPMC5217553
OpenAlexW2569076684

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.